About
Mission/Vision
Our Team
Board of Directors
Elite Members
Why Utah?
Life Sciences Report
Partnerships
Jobs
Membership
Why Join BioUtah?
Membership Prospectus
Apply for Membership
Member Login
Life Sciences Jobs
Member Discounts
Non-dilutive Funding
Membership Directory
Advocacy
News/Info
Biosphere Magazine
Life Sciences News
Reports/Publications
Podcasts
Events
Newsletter
About
Mission/Vision
Our Team
Board of Directors
Elite Members
Why Utah?
Life Sciences Report
Partnerships
Jobs
Membership
Why Join BioUtah?
Membership Prospectus
Apply for Membership
Member Login
Life Sciences Jobs
Member Discounts
Non-dilutive Funding
Membership Directory
Advocacy
News/Info
Biosphere Magazine
Life Sciences News
Reports/Publications
Podcasts
Events
Newsletter
Join Now
Utah Life Sciences News & Events
Dec 15, 2023
January 26, 2025
This week’s newsletter included:
Governor Cox Announces the Launch of the Utah Innovation Fund
BioUtah Podcast Series: “Life Sciences in Action” with Meredith Krannich and Deno Himonas of Wilson Sonsini
Halia Therapeutics Co-Founder David J. Bearss Featured in
Utah Business
Halia Therapeutics Dosed Its First Patient in Phase 2a Clinical Trial of HT-6184, a First-in-Class NLRP3-Inhibitor, for the Treatment of Lower-Risk Myelodysplastic Syndromes
Central Texas Angel Network Makes Significant Investment in Phoenix PharmaLabs
Inherent Biosciences Receives Investment from Utah Innovation Fund
BD Receives FDA 510(k) Clearance for Potentially Transformative Fingertip Blood Collection Device
Two University of Utah Innovators Selected as National Academy of Inventors Fellows
BioHive Wraps Up Food Drive
Metrodora Hosts Governor Cox
Technology Licensing Office at the University of Utah Announces New Processes for Tech Transfer
100 Companies Championing Women
Recent News
BioSeeker™ Powers Development of a First-of-Its-Kind Programmable Therapeutic for Respiratory Syncytial Virus (RSV)
Canary Speech Achieves HITRUST e1 Certification for Voice Biomarker Platform
Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
GE HealthCare’s Economic Impact Across Utah
RefloDx Wins Trans Atlantic Angel Grand Prize